For the second time in the last year, the U.S. International Trade Commission has determined that Apple violated a competitor’s patents in a health-tracking feature of its popular Apple Watch, setting up the devices for a potential ban in the U.S.

As it continues to take advantage of the hole left in the CPAP market by Philips’ ongoing recall, ResMed is still fine-tuning its long-term growth strategy—a process that’s now resulting in short-term shrinkage.

Exela is working with the FDA to recall three separate medications—injectable sodium bicarbonate, midazolam and the nutrition additive Elcys—after inspections of leftover samples flagged silicone matter in some vials.

Sanofi has reported setbacks to a trio of candidates bought in by its business development team, halting (PDF) work or posting negative data on assets picked up from Denali Therapeutics, Kymab and Principia Biopharma.

Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act? In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. On Friday, as AbbVie presented its third-quarter earnings, the company said that it has recorded a $2.1 billion impairment charge based on estimates about “revised cash flows” for Imbruvica.

In a randomized, late-breaking trial presented at the TCT conference, the Esprit BTK implant bested its primary endpoints compared to standard balloon angioplasty alone.

Thursday’s FDA approval of Santhera’s Agamree (vamorolone) to treat Duchenne muscular dystrophy is just a start. The Swiss company is anxious to see how many disorders the first-in-class corticosteroid can treat.